Menu

All Good Things Must Come to an End

| Anne Pacowta

All good things must come to an end, as they did this Monday evening for the fifteen Support Group Leaders (SGLs) who attended American Society of Hematology (ASH) conference this year. For many, it was not the first time at ASH; however, there were two, as we call them, newbies. But as the weekend progressed, […]

New Pathways and Approaches for MM Treatment

| Jim Omel

At ASH, I always look for new ideas and approaches for treating myeloma.  What is new?  What is coming, and what is close to being clinically useful for patients?  Every drug has its start in pre-clinical testing (cell lines), moves on to animal testing, and then makes the move to phase I safety and dosage […]

More Answers or More Questions?

| Teresa Miceli

As the 57th Annual Meeting and Exposition of the American Society of Hematology (ASH) comes to an end, I come to the overwhelming sense that I may now have more questions than answers. Yes, we have had a “November to Remember” with three new drugs receiving Food and Drug Administration (FDA) approval for treating relapsed […]